50results about How to "Reduce myocardial infarct size" patented technology

The invention belongs to the field of medicines, specifically relates to a pharmaceutical composition for treating myocardial ischemia, and particularly relates to a traditional Chinese medicine composition for treating the myocardial ischemia and a preparation method of the traditional Chinese medicine composition. The pharmaceutical composition is prepared from the following traditional Chinese medicine materials in parts by weight: 30-50 parts of codonopsis pilosula, 10-30 parts of vaccaria segetalis, 20-35 pars of panax pseudoginseng, 15-30 parts of semen persicae, 15-35 parts of oenothera biennis and 5-15 parts of medicated leaven. The pharmaceutical composition has simple components, is safe, effective and simple in preparation process, does not have toxic or side effects, is high in patient compliance, and has good development and application prospects.

The invention belongs to the field of medicine, in particular to a pharmaceutical composition for treating myocardial ischemia, in particular to a traditional Chinese medicine composition for treating myocardial ischemia and a preparation method thereof. The pharmaceutical composition is prepared from the following Chinese medicinal materials in parts by weight: 20-40 parts of Panax notoginseng, 10-30 parts of Clematis clematis, 10-30 parts of Piper Piper, 20-40 parts of peach kernel, and 20-40 parts of cassia twig , 10-30 parts of tangerine peel, 10-30 parts of Aescin, 15-35 parts of elderberry, 20-40 parts of astragalus, 5-15 parts of myrrh, 15-35 parts of fairy spleen, 15-35 parts of rehmannia glutinosa . The pharmaceutical composition of the invention is safe and effective, has simple preparation process, no toxic and side effects, high patient compliance, and has very good development and application prospects.

The invention discloses circRNA MNCR nucleotide, a circRNA MNCR nucleotide containing pharmaceutical composition and application thereof. The pharmaceutical composition comprises the circRNA MNCR nucleotide, auxiliary materials, a virus vector or an embedding carrier, wherein the embedding carrier is cholesterol, nanoparticles or liposome and is preferably liposome; the virus vector is one or more of an adenovirus vector, a lentiviral vector and a retroviral vector and is an adenovirus vector preferably; the auxiliary material is one or more of mannitol, phosphate buffer and normal saline and is phosphate buffer preferably; infection titer of the circRNA MNCR virus vector is 10<16>PFU, and a mass ratio of the circRNA MNCR nucleotide to the liposome is 1:1.25; a mass ratio of the virus vector or the embedding vector to the auxiliary material is 1:200. The circRNA MNCR nucleotide and the circRNA MNCR nucleotide containing pharmaceutical composition can be used for prevention and treatment of myocardial hypertrophy, myocardial fibrosis, coronary heart disease and heart failure and prevention of myocardial fibrosis and myocardial remodeling. A preparation process of the pharmaceutical composition is simple, and evident efficacy, convenience in use and environment friendliness in treatment are realized.

The invention discloses a Xuesaitong pharmaceutical composition, its preparation method, preparation and application. The Xuesaitong pharmaceutical composition includes the following pharmaceutical components in mass percentage: 0.001-99.996% of ginsenoside Rb2, 0.001-99.996% of ginsenoside Rb1, 0.001-99.996% of ginsenoside Rg1, 0.001-99.996% of ginsenoside Rc and Notoginsenoside R1 0.001~99.996%. The pharmaceutical composition of the present invention and its preparation are effective for myocardial infarction, cerebral apoplexy, cerebral infarction, cerebral hemiplegia and other ischemic cardiovascular and cerebrovascular diseases, as well as retinopathy or optic nerve damage caused by ischemic cardiovascular and cerebrovascular diseases, diabetes and other reasons. Significant curative effect, has broad application prospects. Compared with the prior art and products, the Xuesaitong medicinal composition and its preparations of the present invention have better curative effect and higher safety, and can better meet the requirements of clinical medication. The preparation method provided by the invention has simple process, mild conditions, convenient operation, stable and controllable quality, and is suitable for large-scale industrial production.